Literature DB >> 32598561

A Systematic Review of Intensive Empirically Supported Treatments for Posttraumatic Stress Disorder.

Nicole A Sciarrino1, Ashlee J Warnecke1, Ellen J Teng1,2,3.   

Abstract

Various clinical practice guidelines for the treatment of posttraumatic stress disorder (PTSD) have consistently identified two frontline evidence-based psychotherapies (EBPs)-prolonged exposure (PE) and cognitive processing therapy (CPT)-as well as other empirically supported treatments (EST), such as eye movement desensitization and reprocessing (EMDR) and cognitive therapy for PTSD (CT for PTSD). However, researchers and clinicians continue to be concerned with rates of symptom improvement and patient dropout within these treatments. Recent attempts to address these issues have resulted in intensive, or "massed," treatments for PTSD. Due to variability among intensive treatments, including treatment delivery format, fidelity to the EST, and the population studied, we conducted a systematic review to summarize and integrate the literature on the impact of intensive treatments on PTSD symptoms. A review of four major databases, with no restrictions regarding publication date, yielded 11 studies that met all inclusion criteria. The individual study findings denoted a large impact of treatment on reduction of PTSD symptoms, ds = 1.15-2.93, and random-effects modeling revealed a large weighted mean effect of treatment, d = 1.57, 95% CI [1.24, 1.91]. Results from intensive treatments also noted high rates of treatment completion (i.e., 0%-13.6% dropout; 5.51% pooled dropout rate across studies). The findings suggest that intensive delivery of these treatments can be an effective alternative to standard delivery and contribute to improved treatment response and reduced treatment dropout. Published 2020. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Year:  2020        PMID: 32598561     DOI: 10.1002/jts.22556

Source DB:  PubMed          Journal:  J Trauma Stress        ISSN: 0894-9867


  7 in total

1.  Intensive outpatient treatment for PTSD: a pilot feasibility study combining prolonged exposure therapy, EMDR, physical activity, and psychoeducation.

Authors:  Trude Julie Brynhildsvoll Auren; Andreas Gjerde Jensen; Julie Rendum Klæth; Elma Maksic; Stian Solem
Journal:  Eur J Psychotraumatol       Date:  2021-05-14

2.  Effectiveness of an intensive treatment programme combining prolonged exposure and EMDR therapy for adolescents suffering from severe post-traumatic stress disorder.

Authors:  Ytje van Pelt; Petra Fokkema; Carlijn de Roos; Ad de Jongh
Journal:  Eur J Psychotraumatol       Date:  2021-05-14

3.  Intensive outpatient treatment for post-traumatic stress disorder: a thematic analysis of patient experience.

Authors:  Ida Haugland Thoresen; Trude Julie Brynhildsvoll Auren; Eva Oddrun Langvik; Charlotte Engesæth; Andreas Gjerde Jensen; Julie Rendum Klæth
Journal:  Eur J Psychotraumatol       Date:  2022-04-20

4.  Distress and post-traumatic stress in parents of patients with congenital gastrointestinal malformations: a cross-sectional cohort study.

Authors:  D Roorda; A F W van der Steeg; M van Dijk; J P M Derikx; R R Gorter; J Rotteveel; J B van Goudoever; L W E van Heurn; J Oosterlaan; L Haverman
Journal:  Orphanet J Rare Dis       Date:  2022-09-11       Impact factor: 4.303

5.  Intensive outpatient treatment for PTSD: an open trial combining prolonged exposure therapy, EMDR, and physical activity.

Authors:  Trude Julie Brynhildsvoll Auren; Julie Rendum Klæth; Andreas Gjerde Jensen; Stian Solem
Journal:  Eur J Psychotraumatol       Date:  2022-10-07

6.  Fully remote intensive trauma-focused treatment for PTSD and Complex PTSD.

Authors:  H Bongaerts; E M Voorendonk; A Van Minnen; L Rozendaal; B S D Telkamp; A de Jongh
Journal:  Eur J Psychotraumatol       Date:  2022-09-22

7.  A brief intervention for PTSD versus treatment as usual: Study protocol for a non-inferiority randomized controlled trial.

Authors:  Halvor Stavland; Camilla Refvik; Jarle Eid; Rafiq Lockhat; Åsa Hammar
Journal:  Trials       Date:  2021-10-25       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.